Importantly, therapeutic disruption of the UBE2V1–HIF-1α axis markedly suppressed HCC tumorigenesis and metastasis in vivo, underscoring its potential as a target for novel therapeutic strategies in HCC. This evidence concerns the gene HIF1A and hepatocellular carcinoma.